Vertex Pharmaceuticals Inc (VRTX.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2012||Chairman of the Board, President, Chief Executive Officer|
|52||2017||Chief Financial Officer, Senior Vice President|
|51||2017||Chief Operating Officer, Executive Vice President|
|42||2017||Executive Vice President, Chief Legal and Administrative Officer|
|52||2015||Executive Vice President - Global Research, Chief Scientific Officer|
- BRIEF-Vertex Receives EU Approval For Orkambi
- BRIEF-Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment
- BRIEF-Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO(ivacaftor)
- BRIEF-Vertex receives CHMP positive opinion for Orkambi for the treatment of children with cystic fibrosis ages 6-11
- Vertex ups cystic fibrosis sales view, but 2 trials fail